COPY NUMBER PROFILING IN ORAL AND OROPHARYNGEAL CANCER CHAPTER 4
radiotherapy resistance. These findings could have implications for de-escalation trials in
HPV-positive OPSCC. Finally, we showed that 11q13 gain is a promising biomarker for predicting occult LNM in patients with clinically Stage I-II OSCC.. Consequently, CNA
profiling increases our understanding of the specific biology of HNSCC and may prove of considerable value to personalizing future cancer therapy in these patients. Disclosure of potential conflicts of interest or financial
SS and WR are working for MRC Holland, the company which developed the MLPA probemix (P428-B1 HNSCC) used in this study.
4
Acknowledgments
The authors would like to thank Shona Kalkman for English proofreading of the manuscript. SMW is funded by the Dutch Cancer Society (clinical fellowship: 2011-4964). RN is funded
by the Dutch Cancer Society (research grant:2014-6620) and Dutch Society for Oral and Maxillofacial Surgery (B.O.O.A. Research Grant 2013)
81